Andrew D. Cherniack

136.4k total citations · 1 hit paper
73 papers, 3.9k citations indexed

About

Andrew D. Cherniack is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrew D. Cherniack has authored 73 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 33 papers in Cancer Research and 19 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrew D. Cherniack's work include Cancer Genomics and Diagnostics (31 papers), Lung Cancer Treatments and Mutations (12 papers) and RNA Research and Splicing (8 papers). Andrew D. Cherniack is often cited by papers focused on Cancer Genomics and Diagnostics (31 papers), Lung Cancer Treatments and Mutations (12 papers) and RNA Research and Splicing (8 papers). Andrew D. Cherniack collaborates with scholars based in United States, Canada and Brazil. Andrew D. Cherniack's co-authors include Matthew Meyerson, Jes K. Klarlund, Michael Czech, Rameen Beroukhim, Peter W. Laird, Hui Shen, Scott L. Carter, Gad Getz, Steven E. Schumacher and Stacey Gabriel and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Andrew D. Cherniack

67 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pan-cancer patterns of somatic copy number alteration

2013 1.2k citations Andrew D. Cherniack, Peter W. Laird et al. profile →

Peers

Countries citing papers authored by Andrew D. Cherniack

Since Specialization

Citations

This map shows the geographic impact of Andrew D. Cherniack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew D. Cherniack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew D. Cherniack more than expected).

Fields of papers citing papers by Andrew D. Cherniack

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew D. Cherniack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew D. Cherniack. The network helps show where Andrew D. Cherniack may publish in the future.

Co-authorship network of co-authors of Andrew D. Cherniack

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew D. Cherniack. A scholar is included among the top collaborators of Andrew D. Cherniack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew D. Cherniack. Andrew D. Cherniack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MYC amplification and MYC protein expression are poor prognostic markers in pediatric and young adult osteosarcoma 2025 ·Cancer ·Matthew Nagy, (unknown), (unknown), (unknown), (unknown), Yvonne Li, Andrew D. Cherniack, Lorena Lazo de la Vega, Matthew Meyerson, Alanna J. Church, Katherine A. Janeway	0
2	Molecular characterization of HER2-negative breast cancers reveals a distinct patient subgroup with 17q12 deletion and heterozygous loss of ERBB2 2025 ·ESMO Open ·Xintao Qiu, (unknown), Rong Li, Albert Grinshpun, Hersh Gupta, Melissa E. Hughes, Gregory J. Kirkner, (unknown), Bruce E. Johnson, (unknown), Andrew D. Cherniack, Ying Jiang, Ning Zhou, Nancy U. Lin, Huan Long, Sara M. Tolaney, Rinath Jeselsohn	0
3	Abstract P5-14-06: Tumor Genomic Landscape in Older Women with Metastatic Breast Cancer (MBC) 2023 ·Cancer Research ·Hersh Gupta, Rachel A. Freedman, Melissa E. Hughes, Yvonne Y. Li, Gregory J. Kirkner, Janet Files, (unknown), Ana C. Garrido-Castro, (unknown), Romualdo Barroso‐Sousa, Brittany Bychkovsky, Sara M. Tolaney, Laura E. MacConaill, Neal Lindeman, Bruce Johnson, Matthew Meyerson, Eric P. Winer, Deborah Dillon, Andrew D. Cherniack, Nancy U. Lin	0
4	Discovery and Features of an Alkylating Signature in Colorectal Cancer 2021 ·Cancer Discovery ·Carino Gurjao, Rong Zhong, Koichiro Haruki, Yvonne Y. Li, Liam F. Spurr, Henry Lee-Six, Brendan Reardon, Tomotaka Ugai, Xuehong Zhang, Andrew D. Cherniack, Mingyang Song, Eliezer M. Van Allen, Jeffrey A. Meyerhardt, Jonathan A. Nowak, Edward L. Giovannucci, Charles S. Fuchs, Kana Wu, Shuji Ogino, Marios Giannakis	42
5	Integrative modeling identifies genetic ancestry-associated molecular correlates in human cancer 2021 ·STAR Protocols ·A. Gordon Robertson, Christina Yau, Jian Carrot‐Zhang, Jeffrey S. Damrauer, Theo Knijnenburg, Nyasha Chambwe, Katherine A. Hoadley, Anab Kemal, Jean C. Zenklusen, Andrew D. Cherniack, Rameen Beroukhim, Wanding Zhou	1
6	Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non–Small Cell Lung Cancer 2020 ·Clinical Cancer Research ·Biagio Ricciuti, Gonzalo Recondo, Liam F. Spurr, Yvonne Y. Li, Giuseppe Lamberti, Deepti Venkatraman, Renato Umeton, Andrew D. Cherniack, Mizuki Nishino, Lynette M. Sholl, Geoffrey I. Shapiro, Mark M. Awad, Michael L. Cheng	102
7	Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities 2020 ·Nature Communications ·(unknown), William J. Gibson, Meredith S. Brown, Jack A. Kosmicki, John Busanovich, (unknown), Laura M. Urbanski, (unknown), Ashton C. Berger, Galen F. Gao, Andrew D. Cherniack, Sirano Dhe‐Paganon, Brenton R. Paolella, Rameen Beroukhim	67
8	Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer 2020 ·Annals of Oncology ·Giuseppe Lamberti, Liam F. Spurr, Y. Li, Biagio Ricciuti, Gonzalo Recondo, Renato Umeton, Mizuki Nishino, Lynette M. Sholl, Matthew Meyerson, Andrew D. Cherniack, Mark M. Awad	66
9	Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12 2020 ·Journal of Biological Chemistry ·Xiaoyun Wu, Gavin R. Schnitzler, Galen F. Gao, (unknown), Andrew R. Baker, Bethany Kaplan, Kaylyn E. Williamson, Lindsay Westlake, Selena Lorrey, Timothy A. Lewis, Colin W. Garvie, Martin Lange, Sikander Hayat, Henrik Seidel, John G. Doench, Andrew D. Cherniack, Charlotte Kopitz, Matthew Meyerson, Heidi Greulich	18
10	MS12.02 Genomic and Functional Approaches to Understanding Cancer Aneuploidy 2019 ·Journal of Thoracic Oncology ·Alison M. Taylor, Juliann Shih, Gavin Ha, Galen F. Gao, (unknown), Ashton C. Berger, Andrew D. Cherniack, Rameen Beroukhim, Matthew Meyerson	3
11	BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II–DNA complexes 2018 ·Proceedings of the National Academy of Sciences ·Hiroyuki Sasanuma, Masataka Tsuda, (unknown), Liton Kumar Saha, (unknown), (unknown), (unknown), Andrew D. Cherniack, Junji Itou, (unknown), Masakazu Toi, Shinichiro Nakada, Hisashi Tanaka, Ken‐Ichiro Tsutsui, Shintaro Yamada, André Nussenzweig, Shunichi Takeda	77
12	PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma 2018 ·Clinical Cancer Research ·Frederik Holst, Henrica M.J. Werner, Siv Mjøs, Erling A. Høivik, Kanthida Kusonmano, Elisabeth Wik, Anna Berg, Even Birkeland, William J. Gibson, Mari K. Halle, Jone Trovik, Andrew D. Cherniack, Karl-Henning Kalland, Gordon B. Mills, Christian F. Singer, Camilla Krakstad, Rameen Beroukhim, Helga B. Salvesen	21
13	Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor 2017 ·Cancer Discovery ·Xiaoyang Zhang, Peter S. Choi, Joshua M. Francis, Galen F. Gao, Joshua D. Campbell, Aruna Ramachandran, Yoichiro Mitsuishi, Gavin Ha, Juliann Shih, Francisca Vázquez, Aviad Tsherniak, Alison M. Taylor, Jin Zhou, Zhong Wu, Ashton C. Berger, Marios Giannakis, William C. Hahn, Andrew D. Cherniack, Matthew Meyerson	85
14	Genomic Activation of PPARG Reveals a Candidate Therapeutic Axis in Bladder Cancer 2017 ·Cancer Research ·Jonathan T. Goldstein, Ashton C. Berger, Juliann Shih, Fujiko Duke, Laura Furst, David J. Kwiatkowski, Andrew D. Cherniack, Matthew Meyerson, Craig A. Strathdee	59
15	RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 α1 and α2 Receptors: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation First-in-Human Study 2017 ·Advances in Therapy ·Catherine S. Tripp, Carolyn A. Cuff, Andrew Campbell, Barbara A. Hendrickson, J W Voss, (unknown), Chengbin Wu, Andrew D. Cherniack, Kenneth Kim	30
16	Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas 2017 ·JAMA Oncology ·Dezheng Huo, Hai Hu, Suhn K. Rhie, Eric R. Gamazon, Andrew D. Cherniack, Jianfang Liu, Toshio F. Yoshimatsu, Jason J. Pitt, Katherine A. Hoadley, Melissa A. Troester, Yuanbin Ru, Tara M. Lichtenberg, Lori A. Sturtz, Carl Simon Shelley, Christopher C. Benz, Gordon B. Mills, Peter W. Laird, Craig D. Shriver, Charles M. Perou, Olufunmilayo I. Olopade	184
17	Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies 2011 ·Cancer Research ·Jeonghee Cho, Sandra Pastorino, Qing Zeng, Xiaoyin Xu, (unknown), Scott R. VandenBerg, Roel G.W. Verhaak, Andrew D. Cherniack, Hideo Watanabe, Amit Dutt, Jihyun Kwon, Ying S. Chao, Robert C. Onofrio, Derek Y. Chiang, Yuki Yuza, Santosh Kesari, Matthew Meyerson	53
18	Function of the Neurospora crassa mitochondrial tyrosyl-tRNA synthetase in RNA splicing. Role of the idiosyncratic N-terminal extension and different modes of interaction with different group I introns 2001 ·Journal of Molecular Biology ·Georg Mohr, Rachel Rennard, Andrew D. Cherniack, (unknown), Alan M. Lambowitz	37
19	Divergent Mechanisms for Homologous Desensitization of p21 by Insulin and Growth Factors 1995 ·Journal of Biological Chemistry ·Jes K. Klarlund, Andrew D. Cherniack, Michael Czech	31
20	Involvement of mitochondrial tyrosyl tRNA synthetase in splicing : identification of an N-terminal domain that functions in splicing / 1991 ·OhioLink ETD Center (Ohio Library and Information Network) ·Andrew D. Cherniack	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact